Literature DB >> 14596759

The economics of direct-to-consumer advertising of prescription-only drugs: prescribed to improve consumer welfare?

Steven Morgan1, Barbara Mintzes, Morris Barer.   

Abstract

According to economic theory, one might expect that the informational content of direct-to-consumer advertising of prescription-only drugs would improve consumers' welfare. However, contrasting the models of consumer and market behaviour underlying this theory with the realities of the prescription-only drug market reveals that this market is distinct in ways that render it unlikely that advertising will serve an unbiased and strictly informative function. A review of qualitative evidence regarding the informational content of drug advertising supports this conclusion. Direct-to-consumer prescription drug advertising concentrates on particular products, and features of those products, to the exclusion of others, and the information provided has frequently been found to be biased or misleading in regulatory and academic evaluations. Governments that have so far resisted direct-to-consumer advertising should invest in independent sources of evidence that could help consumers and professionals to better understand the risks and benefits of treating disease with alternative drug and non-drug therapies, rather than permitting direct-to-consumer prescription drug advertising.

Mesh:

Year:  2003        PMID: 14596759     DOI: 10.1258/135581903322403317

Source DB:  PubMed          Journal:  J Health Serv Res Policy        ISSN: 1355-8196


  5 in total

1.  Time to ban direct-to-consumer prescription drug marketing.

Authors:  Kurt C Stange
Journal:  Ann Fam Med       Date:  2007 Mar-Apr       Impact factor: 5.166

2.  To ban or not to ban? Clinical geneticists' views on the regulation of direct-to-consumer genetic testing.

Authors:  Heidi Carmen Howard; Pascal Borry
Journal:  EMBO Rep       Date:  2012-08-14       Impact factor: 8.807

3.  How does direct-to-consumer advertising (DTCA) affect prescribing? A survey in primary care environments with and without legal DTCA.

Authors:  Barbara Mintzes; Morris L Barer; Richard L Kravitz; Ken Bassett; Joel Lexchin; Arminée Kazanjian; Robert G Evans; Richard Pan; Stephen A Marion
Journal:  CMAJ       Date:  2003-09-02       Impact factor: 8.262

4.  Differences in the information about procedures after cold chain disruption provided by pharmaceutical industry to hospital and community pharmacies.

Authors:  Eleonora M Morais; Teresa M Salgado; Isabel Vazquez Gomez; Andreia M Duarte; Fernando Fernandez-Llimos
Journal:  Eur J Hosp Pharm       Date:  2015-09-30

5.  Direct-to-consumer advertising and expenditures on prescription drugs: a comparison of experiences in the United States and Canada.

Authors:  Steven G Morgan
Journal:  Open Med       Date:  2007-04-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.